Form 8-K - Current report:
SEC Accession No. 0001193125-24-279021
Filing Date
2024-12-16
Accepted
2024-12-16 07:22:30
Documents
17
Period of Report
2024-12-16
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d648282d8k.htm   iXBRL 8-K 39560
2 EX-99.1 d648282dex991.htm EX-99.1 33195
6 GRAPHIC g648282g1216091032518.jpg GRAPHIC 2273
7 GRAPHIC g648282g1216092200273.jpg GRAPHIC 2696
8 GRAPHIC g648282g1216120316055.jpg GRAPHIC 2267
  Complete submission text file 0001193125-24-279021.txt   222059

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20241216.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20241216_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20241216_pre.xml EX-101.PRE 11266
20 EXTRACTED XBRL INSTANCE DOCUMENT d648282d8k_htm.xml XML 3670
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 241550131
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)